title: Results of radiotherapy in primary cutaneous lymphoma.
abstract: BACKGROUND
  Multiple therapeutic strategies have been proposed for the management of primary cutaneous lymphomas. We report the outcome data and therapeutic response of a group of patients treated with local radiotherapy.
  
  
  METHODS
  Twenty seven patients with diagnostic of cutaneous lymphoma and treated with local radiation were evaluated for clinical response. Thirteen cases corresponded to cutaneous T-cell lymphomas (CTCL) and 14 to cutaneous B-cell lymphomas (CBCL). Orthovoltage radiotherapy of 100 Kv was used and total dose of radiation ranged from 15 to 30 Gy (mean 24 Gy; median 20 Gy).
  
  
  RESULTS
  The immediate response to the treatment was satisfactory in all cases. In 24 patients (89%) complete response was obtained in the irradiated lesion and in 3 cases (11%) the response was partial. With a mean follow-up of 25.4 months (range 1-100 months) the overall response rate was 96.3%. Fourteen patients (52%) were alive without evidence of disease (6 CTCL and 8 CBCL), 5 patients (18%) retained cutaneous disease or had systemic progression (3 CTCL and 2 CBCL) and 8 patients died (30%). In 7 patients lymphoma progression was the factor leading to death (26%) and in one patient the cause was not related with the disease.
  
  
  CONCLUSIONS
  Radiotherapy was demonstrated to be able to induce clinical remission of primary cutaneous lymphomas.
authors.affiliation: Department of Radiation Oncology, Hospital Clíni, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universidad de Barcelona, Barcelona, Spain. cconill@clinic.ub.es
authors.forename: Carlos
authors.initials: C
authors.lastname: Conill
authors.forename: Begoña
authors.initials: B
authors.lastname: Navalpotro
authors.forename: Ingrid
authors.initials: I
authors.lastname: López
authors.forename: Teresa
authors.initials: T
authors.lastname: Estrach
mesh_terms: D000328:Adult; D000368:Aged; D002423:Cause of Death; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000532:radiotherapy*; D016410:Lymphoma, T-Cell, Cutaneous / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D011879:Radiotherapy Dosage; D018401:Sample Size; D012878:Skin Neoplasms / Q000532:radiotherapy*; D016019:Survival Analysis; D016896:Treatment Outcome